Entero Therapeutics (ENTO) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ENTO Entero Therapeutics

Watchlist

0.330
-0.110-25.00%

Close Sep 12 16:00 ET

0.344
+0.014+4.27%

Pre 09:09 ET

1.07MMarket Cap-29P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Entero Therapeutics Strikes Deal for Drug Trial Compliance Tech
TipRanksSep 10 07:30 ET
Entero Therapeutics Ink LOI To License Data Vault's Clinical Trial Management Platform For GI Disease Trials
BenzingaSep 10 07:08 ET
Express News | Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform From Data Vault Holdings
ReutersSep 10 07:00 ET
Express News | Reported Friday, Entero Therapeutics Received Nasdaq Notification For Delayed 10-Q Filing, Plans To Regain Compliance By October Deadline
BenzingaAug 26 03:20 ET
Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q
GlobeNewswireAug 23 17:00 ET
Entero Therapeutics Welcomes Timothy Ramdeen to Board
TipRanksAug 15 08:28 ET

Comments

Jaguar8

Sep 10 06:58

NEWS

$Entero Therapeutics (ENTO.US)$
Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings
BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ:ENTO), ("Entero Therapeutics" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced...